These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 26566171)

  • 1. Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia.
    McGarry LJ; Chen YJ; Divino V; Pokras S; Taylor CR; Munakata J; Nieset CC; Huang H; Jabbour E; Malone DC
    Curr Med Res Opin; 2016; 32(2):289-99. PubMed ID: 26566171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
    Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
    Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
    Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
    Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
    J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
    Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
    J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis.
    Hutson TE; Liu FX; Dieyi C; Kim R; Krulewicz S; Kasturi V; Bhanegaonkar A
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1171-1181. PubMed ID: 34165322
    [No Abstract]   [Full Text] [Related]  

  • 9. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
    Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
    Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.
    Atallah EL; Maegawa R; Latremouille-Viau D; Rossi C; Guérin A; Wu EQ; Patwardhan P
    J Health Econ Outcomes Res; 2022; 9(2):19-29. PubMed ID: 35979528
    [No Abstract]   [Full Text] [Related]  

  • 12. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.
    Guérin A; Chen L; Dea K; Wu EQ; Goldberg SL
    J Med Econ; 2014 Feb; 17(2):89-98. PubMed ID: 24188054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia.
    Kropf P; Barnes G; Tang B; Pathak A; Issa JP
    Leuk Lymphoma; 2016; 57(4):935-41. PubMed ID: 26480922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Guérin A; Wu EQ; Bollu VK; Williams D; Guo A; de Leon DP; Quintas-Cardama A
    J Med Econ; 2013; 16(1):125-33. PubMed ID: 22587385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia.
    Machado-Alba JE; Machado-Duque ME
    Int J Clin Pharm; 2017 Aug; 39(4):851-859. PubMed ID: 28508322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q; Borra S; Li J; Wang L; Shrestha S; Sundaram M; Janjan N
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
    Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
    Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
    Winn AN; Keating NL; Dusetzina SB
    J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.